Reduced numbers of naïve CD4 + T cells and an altered CD4/CD8 balance in depressed common variable immune deficiency (CVID) patients. Is thymosin-α1 a possible treatment?

Manusama, Olivia; Singh, Sajni; Brooimans, Rik A.; Wijkhuijs, Annemarie J.M.; Ent, Marianne van der; Drexhage, Hemmo A.; Dalm, Virgil A.S.H.

doi:10.1016/j.intimp.2023.110168

Cited by 2 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tα1 showed remarkable effects in the treatment of acute respiratory distress syndrome, severe acute respiratory syndrome and acute exacerbation of chronic obstructive pulmonary disease, gastrointestinal and systemic infectious disorders ( 70 , 90 , 119 , 120 ). In cystic fibrosis (CF), in which the hyperinflammatory state is associated with early and nonresolving activation of innate immunity, which impairs microbial clearance and promotes a self-sustaining condition of progressive lung damage, Tα1significantly alleviated the symptoms associated with the hyperinflammatory pathology.…”

Section: Tα1 In Medicinementioning

confidence: 99%

Phenotypic drug discovery: a case for thymosin alpha-1

Garaci,

Paci,

Matteucci

et al. 2024

Front. Med.

View full text Add to dashboard Cite

Phenotypic drug discovery (PDD) involves screening compounds for their effects on cells, tissues, or whole organisms without necessarily understanding the underlying molecular targets. PDD differs from target-based strategies as it does not require knowledge of a specific drug target or its role in the disease. This approach can lead to the discovery of drugs with unexpected therapeutic effects or applications and allows for the identification of drugs based on their functional effects, rather than through a predefined target-based approach. Ultimately, disease definitions are mostly symptom-based rather than mechanism-based, and the therapeutics should be likewise. In recent years, there has been a renewed interest in PDD due to its potential to address the complexity of human diseases, including the holistic picture of multiple metabolites engaging with multiple targets constituting the central hub of the metabolic host–microbe interactions. Although PDD presents challenges such as hit validation and target deconvolution, significant achievements have been reached in the era of big data. This article explores the experiences of researchers testing the effect of a thymic peptide hormone, thymosin alpha-1, in preclinical and clinical settings and discuss how its therapeutic utility in the precision medicine era can be accommodated within the PDD framework.

show abstract